Infection Resistant to Multiple Drugs
3
0
0
1
Key Insights
Highlights
Success Rate
50% trial completion
Treatment Research
3 treatments under study, led by Tdm Monitoring Of Neuroand Nephropathology
Research Leaders
8 sponsors active, led by Catholic University of the Sacred Heart
Related Conditions
Often studied with 6 related conditions
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
33.3%
1 terminated out of 3 trials
50.0%
-36.6% vs benchmark
33%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
Aerosolized Plus Intravenous vs. Intravenous Colistin for VAP Due to Pandrugs-resistant A. Baumannii in Neonates
Prospective Observational Pilot-study for the Evaluation of the Nephro- an Neurotoxicity in the Anti-infectious Therapy With Inhalative Colistin Therapy for Patients With Ventilator-associated Pneumonia (VAP)
SATURN 04 Nosocomial Acquisition Study
Research Network
Common Treatments
- Tdm Monitoring Of Neuroand Nephropathology1
- Aerosolized Plus Intravenous Colistin1
- Colistin1
Active Sponsors
- Catholic University of the Sacred Heart1
- University Hospital, Geneva1
- Charite University, Berlin, Germany1
- Clinical Centre of Serbia1
- Hat Yai Medical Education Center1
Top Investigators
Hat Yai Medical Education Center
Charité Universititaetsmedizin Berlin
Università Cattolica del Sacro Cuore - Policlinico A. Gemelli - Roma
Related Conditions
- Bacterial Resistance1
- Pneumonia Ventilatorassociated1
- Infection Due To Esbl Bacteria1
- Staph Aureus Methicillin Resistant Colonization1
- Colistin Adverse Reaction1